Paladin Labs acquires Labopharm Inc.

MONTREAL—Labopharm Inc. and Paladin Labs Inc. have entered into a definitive agreement by which Paladin will acquire all of Labopharm's issued and outstanding shares of common stock for $0.291 per share in cash.

The proposed price offers a 57.4 percent premium over the volume-weighted average price of Labopharm's shares of $0.185 for the 30 trading days prior to the announcement. Labopharm stockholders will be entitled to exercise their options or warrants prior to the agreement's close, and all outstanding Labopharm stock options and warrants will be cancelled. 

"The acquisition of Labopharm represents a unique opportunity for us to further strengthen our pain franchise through the addition of an established revenue stream in international markets with the potential upside provided by several product candidates," said Jonathan Goodman, Paladin's CEO, in a press release. "Moreover, Labopharm's emerging specialty pharmaceutical technology platforms offer longer-term potential in promising new drug fields. Labopharm's expertise and experience around its products and technologies, both in Canada and internationally, will complement our existing capabilities as we execute our growth strategy."

Labopharm's board of directors approved the transaction after a comprehensive review of the offer and its fairness to the company's shareholders.

"The offer from Paladin provides compelling value, certainty and liquidity to our shareholders," said Santo J. Costa, chairman of the Labopharm board, in a press release. "Following a comprehensive review of alternatives under the previously announced strategic review, the board of directors has concluded that this all-cash offer, which is at a significant premium to the trading price of Labopharm's shares, is the best way to maximize shareholder value." 

The closing of the transaction is subject to customary conditions, including the approval of some two-thirds of the votes of Labopharm's shareholders present or represented at a special meeting convened for the purpose of voting on the agreement. The closing is also subject to the approval of the Superior Court of Quebec. The shareholder voting meeting is expected to take place in early October, with details of the agreement to be sent to shareholders in early September. 

In keeping with the agreement, Labopharm is subject to customary non-solicitation covenants, and Paladin maintains the right to match any unsolicited superior proposal that Labopharm might accept. If the agreement should happen to be terminated, as a result of either the board of directors changing its recommendation or if Labopharm terminates the agreement in favor of entering a superior proposal, Labopharm is required to pay Paladin $750,000 as a termination fee.



Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Front Cover

Latest Issue  

• Volume 18 • Issue 12 • December 2022/January 2023

December 2022/January 2023

December 2022/January 2023 issue